Gedeon Richter: Cariprazine shows effectiveness in the treatment for dual disorder
15 Apr 2024
Clinical ResultClinical Study
BUDAPEST, Hungary, April 15, 2024 /PRNewswire/ --
At the 32nd Annual Meeting of the European Psychiatric Association (6-9th April, Budapest, Hungary) new analyses of cariprazine studies were presented by Gedeon Richter Plc. The scientific posters proved that cariprazine might be an appropriate treatment not only for early and late-stage schizophrenia, but also for the difficult-to-treat dual disorder (schizophrenia and comorbid substance use disorder). Furthermore, a new transdiagnostic tool for quantifying, and visualizing symptom severity and functional disability of patients with different psychiatric conditions was presented. A special Gedeon Richter publication, the "Candid Book" was also introduced by the authors, which contains useful, everyday suggestions for the caregivers of patients.
The first Richter poster at the congress provided evidence that cariprazine is effective in treating patients with
late-stage schizophrenia, while the second poster focused on the
early stage of schizophrenia (illness duration of less than 5 years) and the impact of cariprazine in preventing relapse. According to the results, the relative risk of relapse was reduced by 81%. In the third poster,
views of patients and doctors regarding predominant negative symptoms were compared during a 1-year observational study. The final poster was providing information on the potential of cariprazine in
dual disorder, the co-occurrence of a major psychiatric disorder and comorbid substance use disorder. Evidence suggests
that cariprazine is a potential candidate for treatment as it improves symptoms of both disorders: patients experienced improvement in their anxiety, mood, psychotic symptoms, along with reduction in craving and substance consumption.
In addition, Richter organized two scientific sessions: the Product Theatre focused on the topic of "
New treatment options for dual schizophrenia", and a Mini Symposium was organized on the topic of "
Schizophrenia and the management of psychiatric comorbidities", such as affective, anxiety and substance use disorders.
On the 7th of April, during a Scientific Event involving over 250 doctors,
Professor Christoph U. Correll highlighted the importance of using measurements in everyday psychiatric practice, and experts from Gedeon Richter launched a
new transdiagnostic tool for quantifying, and visualizing symptom severity and functional disability of patients with different psychiatric conditions which is available online. During the time of the conference,
Richter's Candid Book – a comprehensive summary of important topics that responds to caregivers' needs in real life situations – was also presented to the professional audience.
About Richter
About Cariprazine
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.